Apellis Pharmaceuticals appoints Dr Robert Kim as CMO
August 8, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Apellis, CMO, GSK, Novartis, appointment
Clinical stage complement immunotherapy company Apellis Pharmaceuticals has named its new chief medical officer as Dr Robert Kim. Kim’s primary …
AbbVie files lawsuit against Amgen over Humira copy
August 8, 2016Research and Development, Sales and Marketing AbbVie, Amgen, FDA, Humira, rheumatoid arthritis
Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis …
The power of PrEP
August 8, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PrEP, high court, lifestyle drug
Many among the general public may not have heard about PrEP, or pre-exposure prophylaxis, before last week when a high …
Opdivo and Keytruda set for India launches by end of year
August 8, 2016Sales and Marketing India, keytruda, launch, opdivo
Indian cancer patients could be set to receive two of the world’s leading oncology drugs, MSD’s Keytruda and Bristol-Myers Squibb’s …
‘Game changer’ asthma pill sees significant reduction in severe symptoms
August 8, 2016Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, university of Leicester
A study at the University of Leicester has found that Fevipiprant (QAW039), the first new asthma pill for nearly 20 …
MSD files Lantus biosimilar with FDA
August 8, 2016Sales and Marketing FDA, Lantus, MK-1293, MSD, application, biosimilar
MSD, known as Merck in the US and Canada, has filed a new drug application with the US Food and …
Shock for BMS as Opdivo misses goal in late-stage lung cancer trial
August 5, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo
Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …
Top ten stories in the pharmaceutical industry this week
August 5, 2016Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk
August 5, 2016Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure
Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …
Majority of US patients’ groups supporting pharma against Medicare reforms received industry funding, claims report
August 5, 2016Medical Communications, Research and Development medicare reform, patients' groups, public citizen
An overwhelming majority of US patients’ groups who supported the pharmaceutical industry in opposing Medicare part B pricing reforms receive …
Eylea sales jump helps boost Regeneron in Q2 results
August 5, 2016Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results
Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …
NICE recommends Cosentyx in ankylosing spondylitis
August 4, 2016Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis
Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …
Merck Q2 results beat analyst estimates
August 4, 2016Medical Communications, Sales and Marketing Merck, financial results
Germany pharmaceutical firm Merck has announced its fiscal results for Q2 2016, beating analyst estimates with earnings before interest, taxes, …
NIH launches test of investigational human Zika vaccine
August 4, 2016Research and Development Vaccine, Zika virus
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun the clinical …
FDA determines Xiamen Origin Biotech wilfully lied to inspectors and customers
August 4, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Xiamen Origin Biotech
The US Food and Drug Administration (FDA) carried out an inspection of Chinese drug manufacturer Xiamen Origin Biotech, finding the …
Bad news for Adaptimmune as partial clinical hold placed on T-cell oncology trial
August 4, 2016Research and Development Adaptimmune, T cell, oncology, t-cell
Adaptimmune Therapeutics has received notice from the US Food and Drug Administration (FDA) that a partial clinical hold has been …
American pharmacy adds 35 products to list of excluded drugs
August 4, 2016Sales and Marketing Drug pricing, cvs health, excluded drugs, hyperinflationary
American pharmacy chain CVS Health has added 35 products to its list of excluded drugs and will not cover certain …
Roche cuts ties with Inovio in hepatitis B development
August 3, 2016Research and Development Inovio, Roche, hepatitis B
Inovio Pharmaceuticals has announced that it will independently continue development of hepatitis B immunotherapy, INO-1800, after Swiss drugmaker Roche issued …
Takeover rumours send Biogen’s stock soaring
August 3, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Biogen, MSD, rumours, takeover
Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a …
Celgene’s Otezla approved for NHS use
August 3, 2016Research and Development, Sales and Marketing Celgene, NHS, NICE, apremilast
NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
